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Abstract
The human organism is a complex structure composed of cells belonging to all three domains of life on Earth, Eukarya, Bacteria and Ar-
chaea, as well as their viruses. Bacterial cells of more than a thousand taxonomic units are condensed in a particular functional collec-
tive domain, the intestinal microbiome. The microbiome constitutes the last human organ under active research. Like other organs, and
despite its intrinsic complexity, the microbiome is readily inherited, in a process probably involving ‘small world’ power law dynamics of
construction in newborns. Like any other organ, the microbiome has physiology and pathology, and the individual (and collective?)
health might be damaged when its collective population structure is altered. The diagnostic of microbiomic diseases involves metage-
nomic studies. The therapeutics of microbiome-induced pathology include microbiota transplantation, a technique increasingly available.
Perhaps a new medical specialty, microbiomology, is being born.
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We are pleased to introduce the present collection of short
reports which correspond to the presentations of the 18th
Scientific Symposium of the Lilly Foundation Spain, entitled
‘Microbiome: Deciphering the Last Organ of the Human
Body’. This title emphasized an important concept: the mi-
crobiome can be regarded as a human organ from the physi-
ological standpoint. Medicine has developed organ-based
specialties such as nephrology, hepatology, cardiology or
pneumology. Perhaps we can envisage ‘microbiomology’ as a
future specialty of or a branch of clinical microbiology,
devoted to the study of the physiology, pathology, diagnos-
tics, therapy and prevention of alterations of the community
structure of the microbiome.
The human organism, like most living organisms, is the
result of stable associations among cells of different origins
and genetic lineages, from mitochondria inside the cells in
the tissues to the microbiota attached to the surfaces of the
human body, integrating members of all three domains of life
on earth, Eukarya, Bacteria and Archaea, and their viruses.
We are definitely not a ‘super-organism’ (a term with inap-
propriate Nietzchean reminiscences), but just a complex
organism with a diversity of genetic compositions. Indeed
the microbiota composition and its relation with the gut
have resulted from the dynamics of selection and competi-
tion [1].
Organisms are identified by their ability to replicate in
well-defined specific lineages. The ‘human lineage’ (human
cells, including mitochondria) is obviously transmitted by ver-
tical descent, but the human microbiota is also transmitted
to the progeny in a less specific but highly reproducible way,
thus giving rise to a consistent heritage of a common core
microbiome with inter-personal variations maintained over
generations within a kinship [2].
As the microbiome is a highly complex structure, involving
several thousands of different bacterial taxonomic units and
therefore millions of links between them, the question
emerging is how this complexity can be inherited.
Stanley Milgram (1933–1984), a social psychologist, was
teaching a long time ago the concept of ‘small world’, illus-
trated by the ‘six degrees of separation’ thought experiment.
Everyone is on average approximately only six steps away,
by way of introduction, from any other person on Earth.
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This happens because there are important nodes (‘hubs’) in
the relational network that help to find other nodes, and
the access to each new node creates new possibilities of
finding individuals, to a certain extent along a power law
dynamics. The application of this concept (without literally
taking into account ‘six steps’) to the rapid building-up of
the extreme complexity of human microbiota is illustrated in
Fig. 1. In humans, a number of ‘starting’ bacteria such as Lac-
tobacillus, Prevotella or Sneathia might be acquired during vagi-
nal delivery [3,4] and possibly other pioneering populations
are acquired by breast feeding [5]. It might be suggested that
these early colonizers serve as sinks or attractors for other
microbial partners (open curves in Fig. 1), and those for oth-
ers thereafter; eventually pairs or higher consortia of organ-
isms create novel niches for other organisms. The
corresponding law of attraction remains one of the most
important items to be investigated in microbiome biology
[5], but it might relate to genomic functional complementar-
ity following genetic reductions, following a model proposed
for bacteria–eukaryotic cell coevolution [6]. As in the ‘small
world’ metaphor, a complex system can be constructed rap-
idly and specifically. Note that, as in an integrated puzzle,
the same system can be constructed from different nodal
origins.
As in other fields of medicine, pathology frequently reveals
the physiology of a system by illustrating the consequences
of alterations and deficiencies. The importance of the mi-
crobiome has been highlighted by the microbial ‘abnormali-
ties’ found in pathological conditions such as inflammatory
bowel diseases, obesity or malnutrition.
Diagnosis of microbiome diseases is based at present on
full metagenomic DNA sequencing and computational
advances that can inform about and differentiate core micro-
biota and changing microbiota [7,8]. These ‘diagnostic’ tech-
niques should also be able to evaluate the role of mobile
genetic elements, which deeply influence the connectivity of
the microbiome [9,10].
The therapy of microbiome diseases will be part of future
interventions based on eco-evo drugs and strategies [11].
The use of prebiotics and probiotics to ‘equilibrate’ altered
human microbiota represent rather empirical approaches
which require much more basic and clinical research to
advance on a scientific basis [12]. Addressing microbiome res-
toration by transplantation is crucial to advance in the curing
of microbiome diseases. This approach has already been used,
with very limited adverse effects, [13] for treating microbiom-
e diseases such as Clostridium difficile associated pathologies,
inflammatory bowel diseases, metabolic syndrome, obesity,
FIG. 1. ‘Small world’ hypothetical steps for
the construction (reproduction) of microbiota.
Upper part, left, a bacterial organism exposing
‘attractors’ (open curves) for other bacterial
partners in the consortium; in the middle, the
partners are present and themselves expose a
variety of novel attractors, and the process
progresses with a power law dynamics on the
right. Lower part, the same schema applied to
intestinal colonization; the host-attached pio-
neer population or community serves as
attractor for other bacterial organisms circu-
lating in the open system that are progres-
sively inserted in the complex system.
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neurodegenerative diseases and autoimmune and allergic dis-
eases [4,14,15]. The possibility of engrafting new microbiota
from a donor source [16] has been demonstrated. Fourteen
days post-transplantation, the recipient microbiota was
shown to be highly similar to the donor [17]. Progress in this
field will be facilitated by using frozen preparations ready for
transplantation [18] and experimental animal models [19].
Microbiota transplantation might also alter host resistance to
infections [20].
A more advanced field of research in the therapy of mi-
crobiome diseases will be the discovery of drugs acting on
host–microbiome and intra-microbiome signals and interac-
tions [21]. However, we reiterate that little is known about
the biochemical signals and micro-ecological structures
assembling the different bacterial populations, and the bases
for their maintenance and coordinate functionality [5].
The fascinating field of microbiome research has just
started to yield knowledge of the multiple consequences of
the alteration of the full microbial complement, a real organ,
which is part of the human body. The relevance for human
body and even human behavioural health will continue to be
revealed in the years to come [2]. This research will stimu-
late integrative thinking to understand integrative complex
structures and will importantly contribute to provide insights
in a future ‘grammar of life’ research. Welcome to microbio-
mology!
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